NCT02849548View on ClinicalTrials.gov

Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

May 17, 2021

Study Completion Date

May 19, 2021

Conditions
Posttraumatic Stress Disorder
Interventions
DRUG

suvorexant

First in class orexin antagonist approved by the FDA for the treatment of insomnia

OTHER

placebo

Pill with inactive ingredients

Trial Locations (1)

20060

Clinical Research Unit; Howard University Hospital, Washington D.C.

All Listed Sponsors
collaborator

Georgetown-Howard Universities Center for Clinical and Translational Science

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Howard University

OTHER

NCT02849548 - Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder | Biotech Hunter | Biotech Hunter